What is a dravet syndrome?
Dravet Syndrome
A severe form of epilepsy beginning in infancy, associated with frequent and prolonged seizures. Epidyolex (CBD oral solution) is NICE-approved and NHS-funded for this condition.
Where you will see it
On the epilepsy page, as one of the conditions the NHS funds Epidyolex for.
EpilepsyRelated terms
- CBD (Cannabidiol)
The second most studied cannabinoid. Non-intoxicating. Has anti-inflammatory, anxiolytic, anticonvulsant, and analgesic properties. Used in Epidyolex (licensed for epilepsy) and as a component in many unlicensed CBPMs.
- Epidyolex
A pharmaceutical-grade CBD oral solution. The only fully licensed cannabis-based medicine in the UK with NICE approval. Indicated for seizures associated with Dravet syndrome and Lennox-Gastaut syndrome in patients aged 2 and above. NHS-funded.
- NICE (National Institute for Health and Care Excellence)
The body that produces evidence-based guidance on health conditions and treatments for use by the NHS. NICE guidance significantly influences NHS prescribing decisions. NICE has approved Epidyolex (TA614 and TA615) but has not recommended CBPMs for most other conditions through the NHS.
- CINV (Chemotherapy-Induced Nausea and Vomiting)
Nausea and vomiting caused by cancer chemotherapy. A well-evidenced indication for cannabinoid medicines including nabilone.
- Lennox-Gastaut Syndrome (LGS)
A severe form of childhood-onset epilepsy characterised by multiple seizure types and intellectual disability. Epidyolex is NICE-approved and NHS-funded for this condition.
This is a plain-language definition for general understanding, not medical or legal advice.
All 101 terms